Patents Assigned to Thallion Pharmaceuticals Inc.
-
Patent number: 8361759Abstract: The present invention provides a scalable process for producing a concentrate containing a mass of a farnesylated dibenzodiazepinone by fermenting in an aqueous culture medium a strain of a microorganism that is capable of producing the farnesylated dibenzodiazepinone, upon completion of fermentation harvesting the fermentation broth and extracting the fermentation broth to provide an extract, and thereafter treating the extract to form the concentrate. The concentrate so produced may be utilized in downstream processes for producing pharmaceutical compounds. A strain of a Micromonospora species capable of producing a farnesylated dibenzodiazepinone at a high yield rate is provided, together with culture media for culturing microorganisms, and fermentation conditions for production of the farnesylated dibenzodiazepinone of the concentrate.Type: GrantFiled: April 21, 2010Date of Patent: January 29, 2013Assignee: Thallion Pharmaceuticals Inc.Inventors: Faustinus Yeboah, Mahmood Piraee
-
Publication number: 20120195891Abstract: The invention features methods, compositions, and kits for treating a subject having a Shiga toxin associated disease with chimeric anti-Shiga Toxin 1 (c?Stx1) and anti-Shiga Toxin 2 (c?Stx2) antibodies.Type: ApplicationFiled: March 6, 2012Publication date: August 2, 2012Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Thallion Pharmaceuticals, Inc.Inventors: Marc Riviere, Claire Thuning-Roberson, Mariam Mehran, Alison O'Brien, Angela Melton-Celsa, Janique Sam-Pan
-
Patent number: 8076287Abstract: The present invention provides cyclic hexadepsipeptides and their pharmaceutically acceptable salts, solvates and prodrugs, and methods for obtaining the compounds, by fermentation, optionally followed by post-biosynthesis chemical modification. The present invention further provides uses of cyclic hexadepsipeptides, and their pharmaceutically acceptable salts, solvates and prodrugs as pharmaceuticals, in particular to their use as antibacterial, antifungal or antineoplastic agents, and to pharmaceutical compositions comprising a cyclic hexadepsipeptide, or a pharmaceutically acceptable salt, solvate or prodrug thereof, together with a carrier.Type: GrantFiled: March 28, 2007Date of Patent: December 13, 2011Assignee: Thallion Pharmaceuticals Inc.Inventors: Emmanuel Zazopoulos, James B. McAlpine, Arjun H. Banskota, Mahmood Piraee
-
Publication number: 20110028458Abstract: The invention relates to the discovery that dibenzodiazepinone analogues have cell migration inhibiting activities on neoplastic and endothelial cells. The migration of neoplastic cells from various tumor types, such as a glioma tumor that may comprise an EGF and/or PTEN mutation, or a Ras-, Raf, or EGFR-mediated tumor, may be inhibited when contacted by the dibenzodiazepinone analogues of the present invention. The invention includes methods for inhibiting migration of a cell in a subject, by contacting a cell with a dibenzodiazepinone analogue of the present invention.Type: ApplicationFiled: April 9, 2009Publication date: February 3, 2011Applicant: THALLION PHARMACEUTICALS INC.Inventors: Borhane Annabi, Martha Maria Cajina Herrera, Henriette Gourdeau
-
Publication number: 20100204468Abstract: The present invention provides a scalable process for producing a concentrate containing a mass of a farnesylated dibenzodiazepinone by fermenting in an aqueous culture medium a strain of a microorganism that is capable of producing the farnesylated dibenzodiazepinone, upon completion of fermentation harvesting the fermentation broth and extracting the fermentation broth to provide an extract, and thereafter treating the extract to form the concentrate. The concentrate so produced may be utilized in downstream processes for producing pharmaceutical compounds. A strain of a Micromonospora species capable of producing a farnesylated dibenzodiazepinone at a high yield rate is provided, together with culture media for culturing microorganisms, and fermentation conditions for production of the farnesylated dibenzodiazepinone of the concentrate.Type: ApplicationFiled: April 21, 2010Publication date: August 12, 2010Applicant: THALLION PHARMACEUTICALS INC.Inventors: Faustinus YEBOAH, Mahmood PIRAEE
-
Patent number: 7655646Abstract: The invention relates to biologically active dibenzodiazepinone analogs represented by Formula I, to methods of producing them, to pharmaceutical compositions comprising them and to methods of treating neoplastic conditions.Type: GrantFiled: December 21, 2007Date of Patent: February 2, 2010Assignee: Thallion Pharmaceuticals, Inc.Inventors: James B. McAlpine, Arjun H. Banskota, Mustapha Aouidate
-
Publication number: 20100016170Abstract: A method for identifying gene cluster is disclosed. The method may be used for identifying gene clusters involved in the biosynthesis of natural products. A small insert library of DNA fragments of genomic DNA and a large insert library of DNA fragments of genomic DNA are prepared. Fragments in the small insert library are sequenced and compared by homology comparison under computer control to a database containing genes, gene fragments or proteins known to be involved in the biosynthesis of microbial natural products. Fragments having similar structure to genes, gene fragments or proteins known to be involved in the biosynthesis of naturally occurring metabolites are used as probes to screen the large insert library of genomic DNA to detect gene clusters involved in the biosynthesis of microbial natural products.Type: ApplicationFiled: May 14, 2007Publication date: January 21, 2010Applicant: Thallion Pharmaceuticals, Inc.Inventors: Chris M. Farnet, Alfredo Staffa, Emmanuel Zazopoulos
-
Patent number: 7635765Abstract: The present invention relates to isolated genetic sequences encoding nonribosomal peptide synthetase (NRPS) proteins which direct the biosynthesis of the antibiotic ramoplanin in microorganisms such as Actinoplanes sp. The isolated gene sequences serve as substrates for bioengineering of antibiotic structures.Type: GrantFiled: August 17, 2005Date of Patent: December 22, 2009Assignee: Thallion Pharmaceuticals, Inc.Inventors: Chris M. Farnet, Emmanuel Zazopoulos, Alfredo Staffa
-
Publication number: 20090258010Abstract: The invention features methods, compositions, and kits for treating a subject having a Shiga toxin associated disease with chimeric anti-Shiga Toxin 1 (c?Stx1) and anti-Shiga Toxin 2 (c?Stx2) antibodies.Type: ApplicationFiled: May 31, 2007Publication date: October 15, 2009Applicant: Thallion Pharmaceuticals, Inc.Inventors: Marc Riviere, Claire Thuning-Roberson, Mariam Mehran, Alison O'Brien, Angela Melton-Celsa, Janique Sam-Pan
-
Publication number: 20090215789Abstract: The present invention provides cyclic hexadepsipeptides and their pharmaceutically acceptable salts, solvates and prodrugs, and methods for obtaining the compounds, by fermentation, optionally followed by post-biosynthesis chemical modification. The present invention further provides uses of cyclic hexadepsipeptides, and their pharmaceutically acceptable salts, solvates and prodrugs as pharmaceuticals, in particular to their use as antibacterial, antifungal or antineoplastic agents, and to pharmaceutical compositions comprising a cyclic hexadepsipeptide, or a pharmaceutically acceptable salt, solvate or prodrug thereof, together with a carrier.Type: ApplicationFiled: March 28, 2007Publication date: August 27, 2009Applicant: THALLION PHARMACEUTICALS, INC.Inventors: Emmanuel Zazopoulos, James B. McAlpine, Arjun H. Banskota, Mahmood Piraee
-
Publication number: 20090186878Abstract: The present invention relates to crystalline forms of ECO-4601 and the processes for providing them. The invention further relates to pharmaceutical compositions comprising the crystalline forms and to methods of use of the crystalline forms as pharmaceuticals.Type: ApplicationFiled: January 26, 2007Publication date: July 23, 2009Applicant: THALLION PHARMACEUTICALS INC.Inventors: Patrick Morris, Faustinus Yeboah, James McAlpine, Maxime Ranger, Emmanuelle Roux, Michael Harvey
-
Publication number: 20090170837Abstract: The invention relates to the discovery that the dibenzodiazepinone analogues have growth inhibiting activities on tumorigenic cells that are driven by expression of RAS or mutated RAS. Thus the invention includes methods for inhibiting the activity of RAS using dibenzodiazepinone analogues; methods for inhibiting the growth of a RAS driven cancer cell using dibenzodiazepinone analogues; methods for inhibiting the growth of a RAS driven cancer using dibenzodiazepinone analogues; and methods for treating a subject having a RAS driven cancer using dibenzodiazepinone analogues.Type: ApplicationFiled: October 24, 2008Publication date: July 2, 2009Applicant: THALLION PHARMACEUTICALS INC.Inventors: Henriette GOURDEAU, Pierre FALARDEAU, Nadia BOUFAIED, Paul Michael CAMPBELL, James John FIORDALISI, Adrienne Deich COX, Channing Joseph DER
-
Patent number: 7521222Abstract: This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivatives, and to methods for obtaining such compounds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain of Micromonospora sp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to Micromonospora sp. strain 046-ECO11, to the use of ECO-04601 and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxygenase, and to pharmaceutical compositions comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.Type: GrantFiled: August 28, 2006Date of Patent: April 21, 2009Assignee: Thallion Pharmaceuticals, Inc.Inventors: Emmanuel Zazopoulos, Chris M. Farnet
-
Publication number: 20090069396Abstract: This invention relates to novel biologically active polyene oxazoles, their pharmaceutically acceptable salts and derivatives, and to methods of obtaining them. One method for obtaining the compounds is by cultivation of Streptomyces sparsogenes NRRL 2940 or a mutant or variant thereof.Type: ApplicationFiled: November 2, 2007Publication date: March 12, 2009Applicant: THALLION PHARMACEUTICALS, INC.Inventors: James B. McAlpine, Chris M. Farnet, Emmanuel Zazopoulos, Nargis Ismail, Brian O. Bachmann
-
Publication number: 20090062255Abstract: The invention relates to a method for evaluating a chemotherapeutic potential of a candidate molecule. In evaluating the candidate molecule, the candidate molecule is tested for its ability to inhibit the in vitro growth of a cancer cell; to bind a cellular receptor produced by a cancer cell, wherein said receptor, such as a peripheral benzodiazepine receptor, is produced in a greater amount by said cancer cell than by a normal cell; and to inhibit the activity of at least one protein member of the MAPK pathway. The invention further relates to dibenzodiazepinone analogues and derivatives thereof.Type: ApplicationFiled: August 15, 2008Publication date: March 5, 2009Applicant: THALLION PHARMACEUTICALS INC.Inventors: Henriette GOURDEAU, Pierre FALARDEAU, My-Anh WIOLAND, Nadia BOUFAIED, James B. MCALPINE, Mustapha AOUIDATE, Thierry BERTOMEU, Ashraf IBRAHIM
-
Patent number: 7462705Abstract: Five protein families cooperate to form the warhead structure that characterizes enediyne compounds, both chromoprotein enediynes and non-chromoprotein enediynes. The protein families include a polyketide synthase and thioesterase protein which form a polyketide synthase catalytic complex involved in warhead formation in enediynes. Genes encoding a member of each of the five protein families are found in all enediyne biosynthetic loci. The genes and proteins may be used in genetic engineering applications to design new enediyne compounds and in methods to identify new enediyne biosynthetic loci.Type: GrantFiled: February 8, 2005Date of Patent: December 9, 2008Assignee: Thallion Pharmaceuticals Inc.Inventors: Chris M. Farnet, Alfredo Staffa, Emmanuel Zazopoulos
-
Patent number: 7416868Abstract: This invention relates to a new class of polyene polyketides, their pharmaceutically acceptable salts and derivatives, and to methods for obtaining the compounds. One method of obtaining these compounds is by cultivation of novel strains of Streptomyces aizunensis; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to the novel strains of Streptomyces aizunensis used to produce these compounds, to the use of these compounds and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of fungal cell growth and cancer cell growth. The invention also relates to pharmaceutical compositions comprising these novel polyketides or a pharmaceutically acceptable salts or derivatives thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of these novel polyketides.Type: GrantFiled: January 21, 2004Date of Patent: August 26, 2008Assignee: Thallion Pharmaceuticals, Inc.Inventors: Emmanuel Zazopoulos, Chris M. Farnet
-
Patent number: 7384935Abstract: This invention relates to phosphate prodrugs of a farnesylated dibenzodiazepinone, to processes of their manufacture, to pharmaceutical compositions comprising the prodrugs, and to their use in the treatment of neoplasms.Type: GrantFiled: September 27, 2006Date of Patent: June 10, 2008Assignee: Thallion Pharmaceuticals, Inc.Inventors: Mustapha Aouidate, James B. McAlpine, Faustinus Yeboah, Ashraf Ibrahim, Arjun H. Banskota, Maxime Ranger, Gregory L. White
-
Publication number: 20080131943Abstract: This invention provides genes and their encoded proteins, involved in the biosynthesis of farnesyl dibenzodiazepinones, including ECO-04601. The invention relates to expression vectors comprising the genes and to host cells transformed with these vectors. The invention further relates to methods of producing farnesyl dibenzodiazepinone compounds using the genes and proteins of the invention, for example, involving expression of biosynthetic pathway genes in transformed host cells.Type: ApplicationFiled: October 22, 2007Publication date: June 5, 2008Applicant: Thallion Pharmaceuticals Inc.Inventors: Chris M. Farnet, Emmanuel Zazopoulos
-
Patent number: 7375088Abstract: This invention relates to a new class of polyene polyketides, their pharmaceutically acceptable salts and derivatives, and to methods for obtaining the compounds. One method of obtaining these compounds is by cultivation of novel strains of Streptomyces aizunensis; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to the novel strains of Streptomyces aizunensis used to produce these compounds, to the use of these compounds and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of fungal cell growth and cancer cell growth. The invention also relates to pharmaceutical compositions comprising these novel polyketides or a pharmaceutically acceptable salts or derivatives thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of these novel polyketides.Type: GrantFiled: January 21, 2004Date of Patent: May 20, 2008Assignee: Thallion Pharmaceuticals Inc.Inventors: Brian O. Bachmann, James B. McAlpine, Emmanuel Zazopoulos, Chris M. Farnet